Sinovac Biotech Co., Ltd.

🇨🇳China

Country: 🇨🇳China

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Safety and Immunogenicity of Concomitant Administration of EV71 Vaccine With Expanded Programme on Immunization Vaccines

Phase 4

Completed

Conditions: Hand, Foot and Mouth Disease

Interventions: Biological: Concomitant administration of EV71vaccine with EPI vaccines
Biological: Single injection of EPI vaccine
Biological: EV71 Vaccine only

First Posted Date: 2019-10-01

Last Posted Date: 2021-07-29

Lead Sponsor: Sinovac Biotech Co., Ltd

Target Recruit Count: 372

Registration Number: NCT04111432

Locations: 🇨🇳
Hanbin District Center for Disease Control and Prevention, Ankang, Shaanxi, China

Clinical Trial of Recombinant Hepatitis B Vaccine (Hansenula Polymorpha, 10μg)

Phase 1

Completed

Conditions: Hepatitis B

Interventions: Biological: Three doses of control vaccine
Biological: One dose of investigational vaccine
Biological: One dose of control vaccine
Biological: Three doses of investigational vaccine

First Posted Date: 2019-08-30

Last Posted Date: 2021-07-29

Lead Sponsor: Sinovac Biotech Co., Ltd

Target Recruit Count: 144

Registration Number: NCT04075201

Locations: 🇨🇳
Biyang County Center for Disease Control and Prevention, Zhumadian, Henan, China

Clinical Trial of Enterovirus 71（EV71） Inactivated Vaccine in Children Aged 36-71 Months

Phase 3

Completed

Conditions: Hand, Foot and Mouth Disease

Interventions: Biological: 36-71 months old children-control EV71 vaccine.
Biological: 36-71 months old children-experimental EV71 vaccine.
Biological: 6-35 months old children-experimental EV71 vaccine.

First Posted Date: 2019-04-09

Last Posted Date: 2022-05-26

Lead Sponsor: Sinovac Biotech Co., Ltd

Target Recruit Count: 900

Registration Number: NCT03909074

Locations: 🇨🇳
Yun County Center for Disease Control and Prevention, Lincang, Yunnan, China

Efficacy Trial of a Commercial EV71 Vaccine

Phase 4

Completed

Conditions: Hand, Foot and Mouth Disease

Interventions: Biological: 5000 volunteers (6-35 months)-EV71 vaccine

First Posted Date: 2019-04-04

Last Posted Date: 2021-07-27

Lead Sponsor: Sinovac Biotech Co., Ltd

Target Recruit Count: 15500

Registration Number: NCT03903926

Locations: 🇨🇳
Songzi Center for Disease Control and Prevention, Jingzhou, Hubei, China
🇨🇳
Xiantao Center for Disease Control and Prevention, Xiantao, Hubei, China

Immunogenicity and Safety of Two Different Commercial EV71 Vaccines

Phase 4

Completed

Conditions: Hand, Foot and Mouth Disease

Interventions: Biological: EV71 inactived vaccine（Vero cells）
Biological: EV71 inactived vaccine（Human diploid cells）

First Posted Date: 2019-03-13

Last Posted Date: 2021-07-29

Lead Sponsor: Sinovac Biotech Co., Ltd

Target Recruit Count: 300

Registration Number: NCT03873740

Locations: 🇨🇳
Rushan City Center for Disease Control and Prevention, Rushan, Shandong, China

Clinical Trial to Evaluate the Safety and Immunogenicity of Quadrivalent Influenza Vaccine (7.5μg/0.25ml)

Phase 3

Completed

Conditions: Seasonal Influenza

Interventions: Biological: Trivalent influenza vaccine (contains B/Yamagata strain)
Biological: Trivalent influenza vaccine (contains B/Victoria strain)
Biological: Quadrivalent influenza vaccine

First Posted Date: 2019-03-01

Last Posted Date: 2019-03-01

Lead Sponsor: Sinovac Biotech Co., Ltd

Target Recruit Count: 2340

Registration Number: NCT03859141

Locations: 🇨🇳
Guanyun Center for Disease Prevention and Control, Lianyungang, Jiangsu, China
🇨🇳
Pizhou Center for Disease Prevention and Control, Pizhou, Jiangsu, China

Clinical Trial to Evaluate the Safety and Immunogenicity of Quadrivalent Influenza Vaccine (15µg/0.5ml)

Phase 3

Completed

Conditions: Seasonal Influenza

Interventions: Biological: Quadrivalent influenza vaccine
Biological: Trivalent influenza vaccine (contains B/Victoria strain)
Biological: Trivalent influenza vaccine (contains B/Yamagata strain)

First Posted Date: 2019-02-26

Last Posted Date: 2019-02-27

Lead Sponsor: Sinovac Biotech Co., Ltd

Target Recruit Count: 2380

Registration Number: NCT03853993

Locations: 🇨🇳
Pizhou Center for Disease Control and Prevention, Pizhou, Jiangsu, China
🇨🇳
Guanyun Center for Disease Control and Prevention, Lianyungang, Jiangsu, China

A Clinical Trial to Evaluate the Immunogenicity and Safety of sIPV in a '1+2' Sequential Schedule With bOPV in Infants

Phase 3

Completed

Conditions: Poliomyelitis

Interventions: Biological: sIPV-bOPV-bOPV vaccination schedule
Biological: wIPV-bOPV-bOPV vaccination schedule

First Posted Date: 2019-01-30

Last Posted Date: 2019-01-30

Lead Sponsor: Sinovac Biotech Co., Ltd

Target Recruit Count: 240

Registration Number: NCT03822754

Locations: 🇨🇳
Guanyun Center for Disease Control and Prevention, Lianyungang, Jiangsu, China

A Clinical Trial to Evaluate the Immunogenicity and Safety of sIPV in a "2+1"Sequential Schedule With bOPV in Infants

Phase 3

Completed

Conditions: Poliomyelitis

Interventions: Biological: sIPV-sIPV-bOPV vaccination schedule
Biological: wIPV-wIPV-bOPV vaccination schedule

First Posted Date: 2019-01-30

Last Posted Date: 2019-01-31

Lead Sponsor: Sinovac Biotech Co., Ltd

Target Recruit Count: 240

Registration Number: NCT03822767

Locations: 🇨🇳
Pizhou Center for Disease Control and Prevention, Xuzhou, Jiangsu, China

An Immunogenicity and Safety Study of Sabin Inactivated Poliovirus Vaccine (Vero Cell) in 2-month-old Infants

Phase 3

Completed

Conditions: Poliomyelitis

Interventions: Biological: Investigational sIPV
Biological: Control IPV

First Posted Date: 2018-05-16

Last Posted Date: 2019-01-25

Lead Sponsor: Sinovac Biotech Co., Ltd

Target Recruit Count: 1200

Registration Number: NCT03526978

Locations: 🇨🇳
Pizhou County Center for Disease Control and Prevention, Pizhou, Jiangsu, China

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy